IPP Bureau
Roche collaborates with PathAI to expand digital pathology capabilities for companion diagnostics
By IPP Bureau - February 14, 2024
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Roche launches three new Factor Xa inhibitor coagulation tests
By IPP Bureau - February 14, 2024
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
By IPP Bureau - February 14, 2024
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar
By IPP Bureau - February 13, 2024
Launches collaborative centre for translational research in head and neck cancer
GSK Q3 FY 2023-24 revenue at Rs. 805 Cr
By IPP Bureau - February 13, 2024
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Sun Pharma included in S&P Global Sustainability Yearbook 2024
By IPP Bureau - February 13, 2024
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
By IPP Bureau - February 13, 2024
These re-agent and diagnostic test kits come with 99.7% accuracy
Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg
By IPP Bureau - February 10, 2024
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
By IPP Bureau - February 10, 2024
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur
By IPP Bureau - February 10, 2024
The 200 bedded hospital owned & operated by Alexis
Zydus Lifesciences Q3 FY24 PAT up 26.8%
By IPP Bureau - February 10, 2024
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline
By IPP Bureau - February 09, 2024
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Growth of Ayush sector is bound to happen: Kotecha
By IPP Bureau - February 09, 2024
Ayush is expanding beyond wellness to therapeutic wellness
Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
By IPP Bureau - February 09, 2024
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
.png "Qure.ai adds new FDA breakthrough device status for qSpot-TB"){kind=logo}
Qure.ai adds new FDA breakthrough device status for qSpot-TB
By IPP Bureau - February 09, 2024
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
